Clinical applications of progesterone receptor antagonists and selective progesterone receptor modulators

Endocrinologist

Volumn 15, Issue 6, 2005, Pages 391-400

  Spitz, Irving M ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Institute of Hormone Research   (Israel)

Author keywords

Asoprisnil; Emergency contraception; Mifepristone; Pregnancy termination; Progesterone receptor antagonists (PRAs); Selective progesterone receptor modulators (SPRMs); Utreine myoma

Indexed keywords

ANTIGESTAGEN; ASOPRISNIL; CONTRACEPTIVE AGENT; DANAZOL; ESTRADIOL; GEMEPROST; GESTAGEN; LUTEINIZING HORMONE; MIFEPRISTONE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ONAPRISTONE; PROGESTERONE RECEPTOR MODULATOR;

ABDOMINAL PAIN; AMENORRHEA; BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; CRANIAL NERVE PARALYSIS; DIARRHEA; DRUG INDICATION; DRUG MECHANISM; DRUG SELECTIVITY; ECTOPIC PREGNANCY; EMERGENCY CONTRACEPTION; ENDOCRINE DISEASE; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; FEMALE; FETUS DEATH; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; FOLLICULAR PHASE; HEADACHE; HUMAN; HYPOESTROGENISM; LIMB DEFECT; LUTEINIZING HORMONE RELEASE; MENSTRUATION DISORDER; MOEBIUS SYNDROME; MUSCLE CRAMP; NAUSEA; NONHUMAN; PEPTIC ULCER; PES EQUINOVARUS; PREGNANCY TERMINATION; REVIEW; SECOND TRIMESTER PREGNANCY; SEPTIC SHOCK; SKULL MALFORMATION; TARGET ORGAN; TERATOGENICITY; UTERUS MYOMA; VOMITING;

EID: 33748625708     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000188472.00222.e6     Document Type: Review

References (127)

1. Philibert D. RU38486: an original multifaceted antihormone in vivo. In: Agarwal M, ed. Adrenal Steroid Antagonism. Berlin: Walter de Gruyter and Co; 1984:77-101.
2. Baulieu E. Contragestion and other clinical applications of RU486, an antiprogesterone at the receptor. Science. 1989;245:1351-1357.
3. Spitz IM, Bardin CW. Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med. 1993;329:404-412.
4. Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol. 1996;36:47-81.
5. DeManno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids. 2003;68:1019-1032.
6. Jang GR, Benet LZ. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharm. 1997;25:647-672.
7. Lahteenmaki P, Heikinheimo O, Croxatto H, et al. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem. 1987;27:859-863.
8. Robbins A, Spitz IM. Mifepristone: clinical pharmacology. Clin Obstet Gynecol. 1996;39:436-450.
9. Leonhardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood). 2002;227:969-980.
10. Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res. 1999;54:291-313; discussion 314.
11. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25:45-71.
12. Liu Z, Auboeuf D, Wong J, et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A. 2002;99:7940-7944.
13. Onate SA, Tsai SY, Tsai MJ, et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270:1354-1357.
14. Senkus Melvin VM, Perez M, Chwalisz K, et al. Mechanism of Action of the Selective Progesterone Receptor Modulator Asoprisnil. In: Annual Meeting of the Endocrine Society; San Diego; 2005:P3 234.
15. McPhail MK. The assay of progestin. J Physiol. 1934;83:145-156.
16. Elger W, Bartley J, Schneider B, et al. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids. 2000;65:713-723.
17. World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ. 1993;307:532-537.
18. Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med. 2000;342:946-956.
19. Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88-92.
20. Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur J Contracept Reprod Health Care. 2000;5:171-176.
21. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001;64:81-85.
22. Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 2000;284:1948-1953.
23. Creinin MD, Schwartz JL, Pymar HC, et al. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. BJOG. 2001;108:469-473.
24. Schaff E, Eisinger S, Stadalius L, et al. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception. 1999;59:1-6.
25. Bartley J, Brown A, Elton R, et al. Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Hum Reprod. 2001;16:2098-2102.
26. Spitz IM, Bardin CW, Benton L, et al. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998;338:1241-1247.
27. Aubeny E, Peyron R, Larquier Turpin C, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil. 1995;40(suppl 2):85-91.
28. Ashok PW, Penney GC, Flett GM, et al. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod. 1998;13:2962-2965.
29. el Refaey H, Rajasekar D, Abdalla M, et al. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med. 1995;332:983-987.
30. Baird DT, Sukcharoen N, Thong KJ. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Hum Reprod. 1995;10:1521-1527.
31. Urquhart D, Templeton A, Shinwei F, et al. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK multicentre study - final results. Contraception. 1997;55:1-5.
32. Ashok PW, Templeton A, Wagaarachchi PT, et al. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. BJOG. 2002;109:1281-1289.
33. Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG. 2002;109:1290-1294.
34. Child TJ, Thomas J, Rees M, et al. A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. Hum Reprod. 2001;16:67-71.
35. Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. Contraception. 2003;67:463-465.
36. Sinave C, Le Templier G, Blouin D, et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis. 2002;35:1441-1443.
37. Wiebe E, Guilbert E, Jacot F, et al. A fatal case of Clostridium sordellii septic shock syndrome associated with medical abortion. Obstet Gynecol. 2004;104:1142-1144.
38. Elam-Evans LD, Strauss LT, Herndon J, et al. Abortion surveillance - United States, 2000. MMWR Surveill Summ. 2003;52:1-32.
39. Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol. 2004;104:174-185.
40. Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet. 1998;352:323.
41. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG. 2000;107:519-523.
42. Fonseca W, Alencar AJ, Mota FS, et al. Misoprostol and congenital malformations. Lancet. 1991;338:56.
43. Gonzalez CH, Vargas FR, Perez AB, et al. Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet. 1993;47:59-64.
44. Gonzalez CH, Marques Dias MJ, Kim CA, et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet. 1998;351:1624-1627.
45. Pastuszak AL, Schuler L, Speck Martins CE, et al. Use of misoprostol during pregnancy and Möbius' syndrome in infants. N Engl J Med. 1998;338:1881-1885.
46. Ashok PW, Kidd A, Flett GMM, et al. A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. Hum Reprod. 2002;17:92-98.
47. Gouk EV, Lincoln K, Khair A, et al. Medical termination of pregnancy at 63 to 83 days gestation. BJOG. 1999;106:535-539.
48. Hamoda H, Ashok PW, Flett GM, et al. Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases. Am J Obstet Gynecol. 2003;188:1315-1319.
49. Ashok PW, Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. BJOG. 1999;106:706-710.
50. Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod. 2000;15:2205-2208.
51. Spitz IM, Bardin CW. Clinical pharmacology of RU 486 - an antiprogestin and antiglucocorticoid. Contraception. 1993;48:403-444.
52. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. Hum Reprod. 1995;10:308-314.
53. Xiao B, von Hertzen H, Zhao H, et al. Menstrual induction with mifepristone and misoprostol. Contraception. 2003;68:489-494.
54. Lelaidier C, Baton Saint Mleux C, Fernandez H, et al. Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod. 1993;8:492-495.
55. Nielsen S, Hahlin M, Platz Christensen JJ. Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue. BJOG. 1997;104:1094-1096.
56. Schaff EA, Fielding SL, Eisinger S, et al. Mifepristone and misoprostol for early abortion when no gestational sac is present. Contraception. 2001;63:251-254.
57. Hughes J, Ryan M, Hinshaw K, et al. The costs of treating miscarriage: a comparison of medical and surgical management. BJOG. 1996;103:1217-1221.
58. el Refaey H, Hinshaw K, Henshaw R, et al. Medical management of missed abortion and anembryonic pregnancy. BMJ. 1992;305:1399.
59. Wagaarachchi PT, Ashok PW, Narvekar N, et al. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod. 2001;16:1849-1853.
60. Wagaarachchi PT, Ashok PW, Smith NC, et al. Medical management of early fetal demise using sublingual misoprostol. BJOG. 2002;109:462-465.
61. Cabrol D, Bouvier D'Yvoire M, Mermet E, et al. Induction of labour with mifepristone after intrauterine fetal death. Lancet. 1985;2:1019.
62. Cabrol D, Dubois C, Cronje H, et al. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. Am J Obstet Gynecol. 1990;163:540-542.
63. Wagaarachchi PT, Ashok PW, Narvekar NN, et al. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. BJOG. 2002;109:443-447.
64. Glasier A, Thong KJ, Dewar M, et al. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med. 1992;327:1041-1044.
65. Webb AM, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ. 1992;305:927-931.
66. Ashok PW, Stalder C, Wagaarachchi PT, et al. A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG. 2002;109:553-560.
67. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002;360:1803-1810.
68. Ashok PW, Wagaarachchi PT, Flett GM, et al. Mifepristone as a late post-coital contraceptive. Hum Reprod. 2001;16:72-75.
69. World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet. 1999;353:697-702.
70. Xiao BL, von Hertzen H, Zhao H, et al. A randomized double-blind comparison of two single doses of mifepristone for emergency contraception. Hum Reprod. 2002;17:3084-3089.
71. Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception. 1998;57:363-369.
72. 'Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med. 1995;333:1517-1521.
73. Piaggio G, von Hertzen H, Heng Z, et al. Meta-analyses of randomized trials comparing different doses of mifepristone in emergency contraception. Contraception. 2003;68:447-452.
74. Hodgen GD, van Uem JF, Chillik CF, et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod. 1994;9(suppl 1):77-81.
75. Slayden OD, Brenner RM. RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab. 1994;78:440-448.
76. Slayden OD, Zelinski Wooten MB, Chwalisz K, et al. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod. 1998;13:269-277.
77. Grow DR, Williams RF, Hsiu JG, et al. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab. 1996;81:1933-1939.
78. Baird DT, Brown A, Critchley HO, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod. 2003;18:61-68.
79. Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids. 2000;65:807-815.
80. Slayden OD, Chwalisz K, Brenner RM. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod. 2001;16:1562-1574.
81. Chwalisz K, Elger W, Stickler T, et al. The effects of one-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in normal women. Hum Reprod. In press.
82. Chwalisz K, Stockemann K, Fritzemeier KH, et al. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum Reprod Update. 1998;4:570-583.
83. Newfield RS, Spitz IM, Isacson C, et al. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf). 2001;54:399-404.
84. Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod. 1994;9(suppl 1):202-207.
85. Grunberg SM, Rankin C, Townsend J, et al. Phase III Double-Blind Randomized Placebo-Controlled Study of Mifepristone (RU) for the Treatment of Unresectable Meningioma. In: American Society of Clinical Oncology; San Francisco, CA; 2001.
86. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74:861-866.
87. Martineau PA, Levental M. Large endometrial polyp in a patient on long-term mifepristone therapy. J Ultrasound Med. 2000;19:487-489.
88. Spitz IM, Grunberg SM, Chabbert-Buffet N, et al. The management of patients on long term treatment with mifepristone. Fertil Steril. In press.
89. Murphy AA, Castellano PZ. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr Opin Obstet Gynecol. 1994;6:269-278.
90. Murphy AA, Kettel LM, Morales AJ, et al. Endometrial effects of long-term low-dose administration of RU486. Fertil Steril. 1995;63:761-766.
91. Eisinger SH, Meldrum S, Fiscella K, et al. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:243-250.
92. Steinauer J, Pritts EA, Jackson R, et al. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004;103:1331-1336.
93. Lamberts SW, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab. 1991;73:187-191.
94. Heikinheimo O, Ranta S, Grunberg S, et al. Alterations in the pituitary-thyroid and pituitary-adrenal axes - consequences of long-term mifepristone treatment. Metabolism. 1997;46:292-296.
95. Heikinheimo O, Ranta S, Grunberg S, et al. Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration. Steroids. 2000;65:831-836.
96. Chwalisz K, Lamar Parker R, Williamson S, et al. Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM). J Soc Gynecol Invest. 2003;10,2(suppl):Abstract 636.
97. Kettel LM, Murphy AA, Morales AJ, et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril. 1993;60:642-646.
98. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996;65:23-28.
99. Kettel LM, Murphy AA, Morales AJ, et al. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol. 1998;178:1151-1156.
100. Yen SSC. Use of antiprogestins in the management of endometriosis and leiomyoma. In: Donaldson MS, Dorflinger L, Brown SS, et al., eds. Clinical Applications of Mifepristone (RU496) and Other Antiprogestins. Washington, DC: National Academy Press; 1993: 189-209.
101. Elger W, Schubert G, Matz S, et al. Effects of the Selective Progesterone Receptor Modulator (SPRM) Asoprisnil on the Morphology of the Genital Tract of Guinea Pigs. In: 12th World Congress on Human Reproduction; Venice, Italy; 2005.
102. Bygdeman M, Danielsson KG, Marions L, et al. Contraceptive use of antiprogestin. Eur J Contracept Reprod Health Care. 1999;4:103-107.
103. Spitz IM, Van Look PF, Coelingh Bennink HJ. The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids. 2000;65:817-823.
104. Croxatto HB, Salvatierra AM, Croxatto HD, et al. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod. 1993;8:201-207.
105. Cameron ST, Critchley HO, Thong KJ, et al. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod. 1996;11:2518-2526.
106. Brown A, Cheng L, Lin S, et al. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab. 2002;87:63-70.
107. Croxatto HB, Kovacs L, Massai R, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod. 1998;13:793-798.
108. Sarkar NN. The potential of mifepristone (RU486) as a female contraceptive drug. Int J Clin Pract. 2002;56:140-144.
109. Borman SM, Schwinof KM, Niemeyer C, et al. Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment. Hum Reprod. 2003;18:69-76.
110. Marions L, Danielsson KG, Swahn ML, et al. Contraceptive efficacy of low doses of mifepristone. Fertil Steril. 1998;70:813-816.
111. Marions L, Viski S, Gemzell-Danielsson K, et al. Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum Reprod. 1999;14:2788-2790.
112. Gemzell Danielsson K, Swahn ML, Svalander P, et al. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod. 1993;8:870-873.
113. Hapangama DK, Brown A, Glasier AF, et al. Feasibility of administering mifepristone as a once a month contraceptive pill. Hum Reprod. 2001;16:1145-1150.
114. Swahn ML, Bygdeman M, Chen JK, et al. Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol. Hum Reprod. 1999;14:485-488.
115. Gemzell Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod. 2002;17:2588-2593.
116. Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod. 2000;15:1969-1972.
117. Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids. 2003;68:1115-1119.
118. Gemzell Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update. 2004;10:341-348.
119. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids. 2003;68:981-993.
120. Spitz IM. Progesterone antagonists and progesterone receptor modulators. Exp Opin Investig Drugs. 2003;12:1693-1707.
121. Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003;68:409-420.
122. Mangal RK, Wiehle RD, Poindexter AN 3rd, et al. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J Steroid Biochem Mol Biol. 1997;63:195-202.
123. Mote PA, Bartow S, Tran N, et al. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72:163-172.
124. McGowan EM, Saad S, Bendall LJ, et al. Effect of progesterone receptor a predominance on breast cancer cell migration into bone marrow fibroblasts. Breast Cancer Res Treat. 2004;83:211-220.
125. Arnett Mansfield RL, deFazio A, Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 2001;61:4576-4582.
126. Graham JD, Yeates C, Balleine RL, et al. Progesterone receptor A and B protein expression in human breast cancer. J Steroid Biochem Mol Biol. 1996;56:93-98.
127. Mote PA, Gompel A, Lavaur A, et al. Progesterone receptor A and B expression predicts response to adjuvant chemotherapy in primary breast cancers. Endocrinologist. 2005.